132 related articles for article (PubMed ID: 38231624)
1. Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.
Cao B; Wang Y; Lu H; Huang C; Yang Y; Shang L; Chen Z; Jiang R; Liu Y; Lin L; Peng P; Wang F; Gong F; Hu H; Cheng C; Yao X; Ye X; Zhou H; Shen Y; Liu C; Wang C; Yi Z; Hu B; Xu J; Gu X; Shen J; Xu Y; Zhang L; Fan J; Tang R; Wang C
N Engl J Med; 2024 Jan; 390(3):230-241. PubMed ID: 38231624
[TBL] [Abstract][Full Text] [Related]
2. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
Hammond J; Leister-Tebbe H; Gardner A; Abreu P; Bao W; Wisemandle W; Baniecki M; Hendrick VM; Damle B; Simón-Campos A; Pypstra R; Rusnak JM;
N Engl J Med; 2022 Apr; 386(15):1397-1408. PubMed ID: 35172054
[TBL] [Abstract][Full Text] [Related]
3. Simnotrelvir as a potential treatment for COVID-19.
McCarthy MW
Expert Opin Pharmacother; 2024 Feb; 25(3):233-237. PubMed ID: 38393345
[TBL] [Abstract][Full Text] [Related]
4. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
[TBL] [Abstract][Full Text] [Related]
5. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
Cao Z; Gao W; Bao H; Feng H; Mei S; Chen P; Gao Y; Cui Z; Zhang Q; Meng X; Gui H; Wang W; Jiang Y; Song Z; Shi Y; Sun J; Zhang Y; Xie Q; Xu Y; Ning G; Gao Y; Zhao R
N Engl J Med; 2023 Feb; 388(5):406-417. PubMed ID: 36577095
[TBL] [Abstract][Full Text] [Related]
6. A first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects.
Yang XM; Yang Y; Yao BF; Ye PP; Xu Y; Peng SP; Yang YM; Shu P; Li PJ; Li S; Hu HL; Li Q; Song LL; Chen KG; Zhou HY; Zhang YH; Zhao FR; Tang BH; Zhang W; Zhang XF; Fu SM; Hao GX; Zheng Y; Shen JS; Xu YC; Jiang XR; Zhang LK; Tang RH; Zhao W
Eur J Pharm Sci; 2023 Dec; 191():106598. PubMed ID: 37783378
[TBL] [Abstract][Full Text] [Related]
7. Olgotrelvir as a Single-Agent Treatment of Nonhospitalized Patients with Covid-19.
Jiang R; Han B; Xu W; Zhang X; Peng C; Dang Q; Sun W; Lin L; Lin Y; Fan L; Lv D; Shao L; Chen Y; Qiu Y; Han L; Kong W; Li G; Wang K; Peng J; Lin B; Tong Z; Lu X; Wang L; Gao F; Feng J; Li Y; Ma X; Wang J; Wang S; Shen W; Wang C; Yan K; Lin Z; Jin C; Mao L; Liu J; Kushnareva Y; Kotoi O; Zhu Z; Royal M; Brunswick M; Ji H; Xu X; Lu H
NEJM Evid; 2024 Jun; 3(6):EVIDoa2400026. PubMed ID: 38804790
[TBL] [Abstract][Full Text] [Related]
8. Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial.
Zhan Y; Lin Z; Liang J; Sun R; Li Y; Lin B; Ge F; Lin L; Lu H; Su L; Xiang T; Pan H; Huang C; Deng Y; Wang F; Xu R; Chen D; Zhang P; Tong J; Wang X; Meng Q; Zheng Z; Ou S; Guo X; Yao H; Yu T; Li W; Zhang Y; Jiang M; Fang Z; Song Y; Chen R; Luo J; Kang C; Liang S; Li H; ; Zheng J; Zhong N; Yang Z
EClinicalMedicine; 2024 Jan; 67():102359. PubMed ID: 38188690
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial.
Olagunju A; Fowotade A; Olagunoye A; Ojo TO; Adefuye BO; Fagbamigbe AF; Adebiyi AO; Olagunju OI; Ladipo OT; Akinloye A; Adeagbo BA; Onayade A; Bolaji OO; Happi C; Rannard S; Owen A
Trials; 2021 Jan; 22(1):3. PubMed ID: 33397457
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial.
Wang F; Xiao W; Tang Y; Cao M; Shu D; Asakawa T; Xu Y; Jiang X; Zhang L; Wang W; Tang J; Huang Y; Yang Y; Yang Y; Tang R; Shen J; Lu H
Lancet Reg Health West Pac; 2023 Sep; 38():100835. PubMed ID: 37484496
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
12. Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19.
Lowe DM; Brown LK; Chowdhury K; Davey S; Yee P; Ikeji F; Ndoutoumou A; Shah D; Lennon A; Rai A; Agyeman AA; Checkley A; Longley N; Dehbi HM; Freemantle N; Breuer J; Standing JF;
PLoS Med; 2022 Oct; 19(10):e1004120. PubMed ID: 36260627
[TBL] [Abstract][Full Text] [Related]
13. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19.
Weinreich DM; Sivapalasingam S; Norton T; Ali S; Gao H; Bhore R; Xiao J; Hooper AT; Hamilton JD; Musser BJ; Rofail D; Hussein M; Im J; Atmodjo DY; Perry C; Pan C; Mahmood A; Hosain R; Davis JD; Turner KC; Baum A; Kyratsous CA; Kim Y; Cook A; Kampman W; Roque-Guerrero L; Acloque G; Aazami H; Cannon K; Simón-Campos JA; Bocchini JA; Kowal B; DiCioccio AT; Soo Y; Geba GP; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD;
N Engl J Med; 2021 Dec; 385(23):e81. PubMed ID: 34587383
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial.
Lu H; Zhang G; Mao J; Chen X; Zhan Y; Lin L; Zhang T; Tang Y; Lin F; Zhu F; Lin Y; Zeng Y; Zhang K; Yuan W; Liang Z; Sun R; Huo L; Hu P; Lin Y; Zhuang X; Wei Z; Chen X; Yan W; Yan X; Mu L; Lin Z; Tu X; Tan H; Huang F; Hu Z; Li H; Li G; Fu H; Yang Z; Chen X; Wang FS; Zhong N
EClinicalMedicine; 2024 May; 71():102582. PubMed ID: 38618202
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial.
Maranda B; Labbé SM; Lurquin M; Brabant P; Fugère A; Larrivée JF; Grbic D; Leroux A; Leduc F; Finzi A; Gaudreau S; Swart Y;
Lancet Infect Dis; 2024 Jan; 24(1):25-35. PubMed ID: 37619584
[TBL] [Abstract][Full Text] [Related]
16. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
Jayk Bernal A; Gomes da Silva MM; Musungaie DB; Kovalchuk E; Gonzalez A; Delos Reyes V; Martín-Quirós A; Caraco Y; Williams-Diaz A; Brown ML; Du J; Pedley A; Assaid C; Strizki J; Grobler JA; Shamsuddin HH; Tipping R; Wan H; Paschke A; Butterton JR; Johnson MG; De Anda C;
N Engl J Med; 2022 Feb; 386(6):509-520. PubMed ID: 34914868
[TBL] [Abstract][Full Text] [Related]
17. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Gottlieb RL; Nirula A; Chen P; Boscia J; Heller B; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Klekotka P; Shen L; Skovronsky DM
JAMA; 2021 Feb; 325(7):632-644. PubMed ID: 33475701
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance, Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19: A Phase 2 Randomized Clinical Trial.
Cairns DM; Dulko D; Griffiths JK; Golan Y; Cohen T; Trinquart L; Price LL; Beaulac KR; Selker HP
JAMA Netw Open; 2022 Feb; 5(2):e2144942. PubMed ID: 35138402
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
20. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Wang Y; Zhang D; Du G; Du R; Zhao J; Jin Y; Fu S; Gao L; Cheng Z; Lu Q; Hu Y; Luo G; Wang K; Lu Y; Li H; Wang S; Ruan S; Yang C; Mei C; Wang Y; Ding D; Wu F; Tang X; Ye X; Ye Y; Liu B; Yang J; Yin W; Wang A; Fan G; Zhou F; Liu Z; Gu X; Xu J; Shang L; Zhang Y; Cao L; Guo T; Wan Y; Qin H; Jiang Y; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
Lancet; 2020 May; 395(10236):1569-1578. PubMed ID: 32423584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
